Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review

Charlotte Suppli UlrikDepartment of Respiratory Medicine, Hvidovre Hospital and University of Copenhagen, Hvidovre, DenmarkBackground and aim: Long-acting bronchodilators are the preferred option for maintenance therapy of patients with chronic obstructive pulmonary disease (COPD). The aim of this r...

Full description

Bibliographic Details
Published in:	International Journal of COPD
Main Author:	Ulrik CS
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-04-01
Online Access:	http://www.dovepress.com/clinical-benefit-of-fixed-dose-dual-bronchodilation-with-glycopyrroniu-a16298

Similar Items

Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit
by: Ulrik CS
Published: (2012-09-01)

Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life
by: Rossi A, et al.
Published: (2015-07-01)

Medication Adherence and Asthma Control with Once-Daily Indacaterol/Glycopyrronium/Mometasone Furoate Breezhaler Digital Companion: 90-Day Analysis from Germany
by: Holger Woehrle, et al.
Published: (2023-04-01)

Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study
by: Hsieh MJ, et al.
Published: (2022-04-01)

Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone
by: Shamim Ahmed, et al.
Published: (2022-02-01)

Interactions between glycopyrronium and indacaterol on cholinergic neurotransmission and contractile response in bovine trachealis
by: Michele Baroffio, et al.
Published: (2017-07-01)

NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY
by: S. N. AVDEEV
Published: (2016-12-01)

Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses
by: Richard N. van Zyl-Smit, et al.
Published: (2023-08-01)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England
by: Requena G, et al.
Published: (2023-09-01)

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study
by: Wang C, et al.
Published: (2015-01-01)

Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease
by: Hataji O, et al.
Published: (2012-12-01)

Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety
by: Erminia Ridolo, et al.
Published: (2015-04-01)

Profiling the bronchodilator effects of the novel ultra-long-acting β-agonist indacaterol against established treatments in chronic obstructive pulmonary disease
by: Claus Vogelmeier, et al.
Published: (2011-10-01)

Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropiumolodaterol in patients with chronic obstructive pulmonary disease
by: S. K. Zyryanov, et al.
Published: (2018-04-01)

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease
by: Nishijima Y, et al.
Published: (2015-02-01)

A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study
by: Juvelekian G, et al.
Published: (2015-10-01)

The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study
by: Christianne M. Blais, et al.
Published: (2017-08-01)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
by: Strange C, et al.
Published: (2019-06-01)

Glycopyrronium inhalation, bronchodilator reversibility assessment, and defining asthma: A new paradigm
by: Parthasarathi Bhattacharyya, et al.
Published: (2024-06-01)

Comparative efficacy of indacaterol in chronic obstructive pulmonary disease
by: Ribeiro M, et al.
Published: (2012-03-01)

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
by: Leif Bjermer, et al.
Published: (2017-12-01)

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
by: Claus F. Vogelmeier, et al.
Published: (2017-07-01)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
by: Antonio R. Anzueto, et al.
Published: (2018-06-01)

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]
by: Dahl R, et al.
Published: (2014-01-01)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
by: Donohue JF, et al.
Published: (2019-12-01)

Fixed dose long-acting bronchodilator combinations in chronic obstructive pulmonary disease: safety, effectiveness and cardiovascular system
by: I. V. Leshchenko
Published: (2018-10-01)

Effects of combination therapy indacaterol/glycopyrronium versus tiotropium on moderate to severe COPD: evaluation of impulse oscillometry and exacerbation rate
by: Antonio Molino, et al.
Published: (2017-09-01)

Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach
by: Lakhotia B, et al.
Published: (2020-04-01)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
by: Wedzicha JA, et al.
Published: (2017-01-01)

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
by: Vogelmeier C, et al.
Published: (2016-12-01)

Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis.
by: Vincent C H Chung, et al.
Published: (2013-01-01)

New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease
by: S N Avdeev, et al.
Published: (2019-03-01)

Efficacy and safety of indacaterol 150 <it>μ</it>g once-daily in COPD: a double-blind, randomised, 12-week study
by: Piggott Simon, et al.
Published: (2010-03-01)

Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium tiotropium: the RED trial
by: Jessie Beaulieu, et al.
Published: (2020-07-01)

Rapid simultaneous determination of indacaterol maleate and glycopyrronium bromide in inhaler capsules using a validated stability-indicating monolithic LC method
by: Sahar Zayed, et al.
Published: (2017-05-01)

BRONCHOPROTECTIVE EFFECT OF GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
by: I. N. Trofimenko, et al.
Published: (2017-11-01)

Once-Daily Dosing of Aminoglycosides
by: William A Craig
Published: (1994-01-01)

Is dual bronchodilator therapy the new GOLD standard for initiating treatment for chronic obstructive pulmonary disease?
by: Ashutosh Nath Aggarwal
Published: (2023-01-01)

Fixed-dose combinations of bronchodilators in the treatment of patients with COPD: problem of choice
by: A. I. Sinopalnikov
Published: (2018-10-01)

Benefits of once-daily therapies in the treatment of hypertension
by: Flack J
Published: (2011-12-01)